Compare DexCom, Inc. (DXCM) vs Nvidia Corp (NVDA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Nvidia Corp — how do they compare? DexCom, Inc. trades at $84.38 (market cap $31.86B), while Nvidia Corp trades at $234.01 (market cap $5.57T). The key difference: Nvidia Corp is far larger — about 174.8× DexCom, Inc.'s market cap, and Nvidia Corp pays a 0.43% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Nvidia Corp for 115 Days on average.
| DXCM | NVDA | |
|---|---|---|
Market Cap | $31.86B | $5.57T |
Volume | 3,607,070 | 117,720,595 |
Sector | Health | Technology |
52-Week High | $92.34 | $239.27 |
52-Week Low | $54.84 | $165.17 |
Typical Hold Time | 62 Days | 115 Days |
Enterprise Value | $31.32B | $5.54T |
Dividend Yield | — | 0.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $84.3, up 1.09% today, with a bearish technical signal despite strong fundamentals. The company reported Q2 2026 EPS of $0.70, beating estimates, continuing a trend of earnings outperformance. Revenue growth is robust, with 2025 revenue reaching $4.66 billion and net income margin improving to 20.12%. Analyst consensus is strongly bullish with an 80.77% buy rating and a $95.07 price target, suggesting significant upside from current levels.
The outlook for DXCM is positive driven by expansion in continuous glucose monitoring for Type 2 diabetes, as highlighted in recent company reports. Key risks include competitive pressures and reimbursement challenges. With solid cash flow generation and institutional support, the stock presents a growth opportunity, though investors should monitor execution against high expectations.
NVIDIA (NVDA) trades at $237.36, down 0.8% on the day, amid a broader tech sector rotation. The stock exhibits a bullish technical trend, supported by strong fundamentals including a 55.84% net income margin and consistent earnings beats. Revenue growth accelerated to $130.50 billion in 2025, with analyst consensus remaining overwhelmingly positive.
The outlook for NVDA is favorable, driven by sustained AI chip demand and a $339.17 average price target implying significant upside. Key risks include heightened competition, market volatility from geopolitical tensions, and the stock's premium valuation. Long-term growth prospects remain robust, though near-term volatility may persist.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Nvidia Corp
NVIDIA Corporation designs, develops, and markets three dimensional (3D) graphics processors and related software. The Company offers products that provides interactive 3D graphics to the mainstream personal computer market.
Read more on NVDA →
